Compare · MRNA vs TSBX
MRNA vs TSBX
Side-by-side comparison of Moderna Inc. (MRNA) and Turnstone Biologics Corp. (TSBX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TSBX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA carries a market cap of $94.42B.
- MRNA has hit the wire 11 times in the past 4 weeks while TSBX has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 6 for TSBX).
- Company
- Moderna Inc.
- Turnstone Biologics Corp.
- Price
- -
- -
- Market cap
- $94.42B
- -
- 1M return
- +37.67%
- -
- 1Y return
- +737.05%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2023
- News (4w)
- 11
- 0
- Recent ratings
- 25
- 6
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- SEC Form 4 filed by Moderna Inc.
- AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test
- Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
- SEC Form 4 filed by Moderna Inc.
- 2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope
- SEC Form 3 filed by Moderna Inc.
- Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026
- Moderna downgraded by Citigroup with a new price target
- Moderna Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Moderna Adds Chief Operating Officer Role as Company Expands into Oncology
Latest TSBX
- SEC Form 15-12G filed by Turnstone Biologics Corp.
- SEC Form 4 filed by Director Orbimed Advisors Llc
- Amendment: SEC Form SCHEDULE 13D/A filed by Turnstone Biologics Corp.
- SEC Form 4 filed by Large owner Versant Ventures V, Llc
- SEC Form S-8 POS filed by Turnstone Biologics Corp.
- SEC Form S-8 POS filed by Turnstone Biologics Corp.
- Turnstone Biologics Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant
- Amendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.
- SEC Form 25-NSE filed by Turnstone Biologics Corp.
- Amendment: SEC Form SC TO-T/A filed by Turnstone Biologics Corp.